New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Proposed combination enhances Pfizer’s position as a leading company in oncology
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The inspection concluded with no observations
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Subscribe To Our Newsletter & Stay Updated
